Skip to main content
Top
Published in: Endocrine 2/2017

01-02-2017 | Original Article

Hyperinsulinemia and obese phenotype differently influence blood pressure in young normotensive patients with polycystic ovary syndrome

Authors: Roberto Mioni, Anna Dalla Cà, Jenni Turra, Sara Azzolini, Nadia Xamin, Luigi Bleve, Pietro Maffei, Roberto Vettor, Francesco Fallo

Published in: Endocrine | Issue 2/2017

Login to get access

Abstract

To differentiate the impact of insulin levels/resistance per se from that of excess weight on blood pressure (BP) daily changes, we evaluated, using 24-h ambulatory blood pressure monitoring (ABPM), systolic blood pressure (SBP) and diastolic blood pressure (DBP) in a cohort of young normotensive patients affected by polycystic ovary syndrome (PCOS). A cross-sectional study was performed. Fifty-four patients were studied according to (a) insulinemic state: 32 hyperinsulinemic and/or insulin-resistant (h-INS) and 22 normoinsulinemic (n-INS) patients; and (b) body mass index (BMI): 22 obese (BMI > 30) and 32 lean (18.0 < BMI < 24.9) patients. Each subject’s SBP and DBP and heart rate (HR) were measured by ABPM. Supine and upright plasma renin activity (PRA), and aldosterone levels were also assayed. Patients in the h-INS group showed higher 24-h, daytime, and nighttime diastolic blood pressure (DBP), higher nighttime systolic blood pressure (SBP) levels, as well as an increased 24-h, daytime and nighttime HR, compared to both obese and lean patients in the n-INS group. In relation to BMI, only 24-h, daytime, and nighttime DBP were higher in obese than in lean patients. At variance, when both h-INS and obesity were considered, 24-h SBP and DBP were higher in h-INS obese subjects than in the other groups. In multivariate analysis, insulin (max peak), area under the curve of insulin and insulin sensitivity index was independently associated with SBP. (1) Within a normotensive range, hyperinsulinemia and/or insulin resistance influence daily BP variation more than obesity does, suggesting a pivotal role of insulin on BP control in PCOS; (2) altered insulinemic state and ABPM-derived higher nighttime BP and HR may represent early markers to identify PCOS subjects prone to high cardiovascular risk.
Literature
1.
go back to reference W.A. March, V.M. Moore, K. Wilson, D.I.W. Philipps, R.J. Norman, M.J. Davies, The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum. Reprod. 25, 544–551 (2010)CrossRefPubMed W.A. March, V.M. Moore, K. Wilson, D.I.W. Philipps, R.J. Norman, M.J. Davies, The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum. Reprod. 25, 544–551 (2010)CrossRefPubMed
2.
go back to reference R. Azziz, K.S. Woods, R. Reyena, T.J. Key, E.S. Knochenhauer, B.O. Yildiz, The prevalence and features of the polycystic ovary syndrome in unselected population. J. Clin. Endocrinol. Metab. 89, 2745–2749 (2004)CrossRefPubMed R. Azziz, K.S. Woods, R. Reyena, T.J. Key, E.S. Knochenhauer, B.O. Yildiz, The prevalence and features of the polycystic ovary syndrome in unselected population. J. Clin. Endocrinol. Metab. 89, 2745–2749 (2004)CrossRefPubMed
3.
go back to reference E. Carmina, S.E. Obersfield, R.A. Lobo, The diagnosis of polycystic ovary syndrome in adolescents. Am. J. Obstet. Gynecol. 203, 201–205 (2010)CrossRefPubMed E. Carmina, S.E. Obersfield, R.A. Lobo, The diagnosis of polycystic ovary syndrome in adolescents. Am. J. Obstet. Gynecol. 203, 201–205 (2010)CrossRefPubMed
4.
go back to reference S. Franks, Polycystic ovary syndrome. N. Engl. J. Med. 33, 853–861 (1995)CrossRef S. Franks, Polycystic ovary syndrome. N. Engl. J. Med. 33, 853–861 (1995)CrossRef
5.
go back to reference A.M. Scarpitta, D. Sinagra, Polycystic ovary syndrome: an endocrine and metabolic disease. Gynecol. Endocrinol. 14, 392–395 (2000)CrossRefPubMed A.M. Scarpitta, D. Sinagra, Polycystic ovary syndrome: an endocrine and metabolic disease. Gynecol. Endocrinol. 14, 392–395 (2000)CrossRefPubMed
6.
go back to reference S. Sam, A. Dunaif, Polycystic ovary syndrome: syndrome XX? Trend Endocrinol Met. 14, 365–370 (2003)CrossRef S. Sam, A. Dunaif, Polycystic ovary syndrome: syndrome XX? Trend Endocrinol Met. 14, 365–370 (2003)CrossRef
7.
go back to reference D. Cibula, J. Škrha, M. Hill, M. Fanta, L. Haaková, J. Vrbĺková, J. Živný, Prediction of insulin sensitivity in nonobese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87(12), 5821–5829 (2002)CrossRefPubMed D. Cibula, J. Škrha, M. Hill, M. Fanta, L. Haaková, J. Vrbĺková, J. Živný, Prediction of insulin sensitivity in nonobese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87(12), 5821–5829 (2002)CrossRefPubMed
9.
go back to reference R.A. Wild, E. Carmina, E. Diamanti-Kandarakis, A. Dokras, H.F. Escobar-Morreale, W. Futterweit, R. Lobo, R.J. Norman, E. Talbott, D.A. Dumesic, Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 6(4), 244–249 (2013) R.A. Wild, E. Carmina, E. Diamanti-Kandarakis, A. Dokras, H.F. Escobar-Morreale, W. Futterweit, R. Lobo, R.J. Norman, E. Talbott, D.A. Dumesic, Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 6(4), 244–249 (2013)
10.
go back to reference B.G. Stuckey, N. Opie, A.J. Cusson, G.F. Watss, V. Brike, Clustering of metabolic and cardiovascular risk factors in the polycystic ovary syndrome: a principal component analysis. Metabolism 63(8), 1071–1077 (2014)CrossRefPubMed B.G. Stuckey, N. Opie, A.J. Cusson, G.F. Watss, V. Brike, Clustering of metabolic and cardiovascular risk factors in the polycystic ovary syndrome: a principal component analysis. Metabolism 63(8), 1071–1077 (2014)CrossRefPubMed
11.
go back to reference A.E. Joham, J.A. Boyle, S. Zoungas, H.J. Teede, Hypertension in reproductive-aged women with polycystic ovary syndrome and association with obesity. Am. J. Hypertens. 28(7), 847–851 (2015)CrossRefPubMed A.E. Joham, J.A. Boyle, S. Zoungas, H.J. Teede, Hypertension in reproductive-aged women with polycystic ovary syndrome and association with obesity. Am. J. Hypertens. 28(7), 847–851 (2015)CrossRefPubMed
12.
go back to reference H.S. Randeva, B.K. Tan, M.O. Weickert, K. Lois, J.E. Nestler, N. Sattar, H. Lehnert, Cardiometabolic aspects of the polycystic ovary syndrome. Endocr. Rev. 33(5), 812–841 (2012)CrossRefPubMedPubMedCentral H.S. Randeva, B.K. Tan, M.O. Weickert, K. Lois, J.E. Nestler, N. Sattar, H. Lehnert, Cardiometabolic aspects of the polycystic ovary syndrome. Endocr. Rev. 33(5), 812–841 (2012)CrossRefPubMedPubMedCentral
13.
go back to reference R. Murray, Polycystic ovary syndrome, obesity and insulin resistance: the new female triade. Adv. Nurs. Prac. 12, 22–35 (2004) R. Murray, Polycystic ovary syndrome, obesity and insulin resistance: the new female triade. Adv. Nurs. Prac. 12, 22–35 (2004)
14.
go back to reference M. Salehi, Pathogenesis of polycystic ovary syndrome: what is the role of obesity? Metabolism 53, 358–376 (2004)CrossRefPubMed M. Salehi, Pathogenesis of polycystic ovary syndrome: what is the role of obesity? Metabolism 53, 358–376 (2004)CrossRefPubMed
15.
go back to reference Y.A. Sung, J.Y. Oh, H. Chung, H. Lee, Hyperandrogenemia is implicated in both the metabolic and reproductive morbidities of polycystic ovary syndrome. Fertil. Steril. 101(3), 840–845 (2014)CrossRefPubMed Y.A. Sung, J.Y. Oh, H. Chung, H. Lee, Hyperandrogenemia is implicated in both the metabolic and reproductive morbidities of polycystic ovary syndrome. Fertil. Steril. 101(3), 840–845 (2014)CrossRefPubMed
16.
go back to reference J. Zhang, P. Fan, H. Liu, H. Bai, Y. Wang, F. Zhang, Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS. Hum. Reprod. 27(8), 2484–2493 (2012)CrossRefPubMed J. Zhang, P. Fan, H. Liu, H. Bai, Y. Wang, F. Zhang, Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS. Hum. Reprod. 27(8), 2484–2493 (2012)CrossRefPubMed
17.
go back to reference N.M. Daan, Y.V. Louwers, M.P. Koster, M.J. Eijkemans, Y.B. de Rijke, E.W. Lentjes, B.C. Fauser, Laven JS Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? Fertil. Steril. 102(5), 1444–1451 (2014)CrossRefPubMed N.M. Daan, Y.V. Louwers, M.P. Koster, M.J. Eijkemans, Y.B. de Rijke, E.W. Lentjes, B.C. Fauser, Laven JS Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? Fertil. Steril. 102(5), 1444–1451 (2014)CrossRefPubMed
18.
go back to reference Y. Shi, Y. Cui, X. Sun, G. Ma, Z. Ma, Q. Gao, Z.J. Chen, Hypertension in women with polycystic ovary syndrome: prevalence and associated cardiovascular risk factors. Eur. J. Obstet. Gynecol. Reprod. Biol. 173, 66–70 (2014)CrossRefPubMed Y. Shi, Y. Cui, X. Sun, G. Ma, Z. Ma, Q. Gao, Z.J. Chen, Hypertension in women with polycystic ovary syndrome: prevalence and associated cardiovascular risk factors. Eur. J. Obstet. Gynecol. Reprod. Biol. 173, 66–70 (2014)CrossRefPubMed
19.
go back to reference R.S. Bernstein, L.N. Meurer, E.J. Plumb, J.L. Jackson, Diabetes and hypertension prevalence in homeless adults in the United States: a systematic review and meta-analysis. Am. J. Public Health 105(2), e46–e60 (2015)CrossRefPubMedPubMedCentral R.S. Bernstein, L.N. Meurer, E.J. Plumb, J.L. Jackson, Diabetes and hypertension prevalence in homeless adults in the United States: a systematic review and meta-analysis. Am. J. Public Health 105(2), e46–e60 (2015)CrossRefPubMedPubMedCentral
20.
go back to reference Canadian Agency for Drugs and Technologies in Health, Obesity management interventions delivered in primary care for patients with hypertension or cardiovascular disease: a review of clinical effectiveness (Ottawa, ON, 2014 Canadian Agency for Drugs and Technologies in Health, Obesity management interventions delivered in primary care for patients with hypertension or cardiovascular disease: a review of clinical effectiveness (Ottawa, ON, 2014
21.
go back to reference B.C. Wingo, T.L. Carson, J. Ard, Differences in weight loss and health outcomes among African Americans and whites in multicentre trials. Obes. Rev. 15(Suppl 4), 46–61 (2014)CrossRefPubMed B.C. Wingo, T.L. Carson, J. Ard, Differences in weight loss and health outcomes among African Americans and whites in multicentre trials. Obes. Rev. 15(Suppl 4), 46–61 (2014)CrossRefPubMed
22.
go back to reference Y. Imai, A. Aihara, T. Ohkubo, K. Nagai, I. Tsuji, N. Minami, H. Satoh, S. Hisamichi, Factors that affect blood pressure variability. A community-based study in Ohasama, Japan. Am. J. Hypertens. 10, 1281–1289 (1997)CrossRefPubMed Y. Imai, A. Aihara, T. Ohkubo, K. Nagai, I. Tsuji, N. Minami, H. Satoh, S. Hisamichi, Factors that affect blood pressure variability. A community-based study in Ohasama, Japan. Am. J. Hypertens. 10, 1281–1289 (1997)CrossRefPubMed
23.
go back to reference C. Cuspidi, G. Macca, L. Sampieri, V. Fusi, B. Severgnini, I. Michev, M. Salerno, F. Magrini, A. Zanchetti, Target organ damage and non-dipping pattern defined by two sessions of ambulatory blood pressure monitoring in recently diagnosed essential hypertensive patients. J. Hypertens. 19, 1539–1545 (2001)CrossRefPubMed C. Cuspidi, G. Macca, L. Sampieri, V. Fusi, B. Severgnini, I. Michev, M. Salerno, F. Magrini, A. Zanchetti, Target organ damage and non-dipping pattern defined by two sessions of ambulatory blood pressure monitoring in recently diagnosed essential hypertensive patients. J. Hypertens. 19, 1539–1545 (2001)CrossRefPubMed
24.
go back to reference T. Ohkubo, A. Hozawa, J. Yamaguchi, M. Kikuya, K. Ohmori, M. Michimata, M. Matsubara, J. Hashimoto, H. Hoshi, T. Araki, I. Tsuji, H. Satoh, S. Hisamichi, Y. Imai, Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J. Hypertens. 20, 2183–2189 (2002)CrossRefPubMed T. Ohkubo, A. Hozawa, J. Yamaguchi, M. Kikuya, K. Ohmori, M. Michimata, M. Matsubara, J. Hashimoto, H. Hoshi, T. Araki, I. Tsuji, H. Satoh, S. Hisamichi, Y. Imai, Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J. Hypertens. 20, 2183–2189 (2002)CrossRefPubMed
25.
go back to reference Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, Revised 2003 Consensus on diagnostic criteria and long-term health risk related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19(1), 41–47 (2004)CrossRef Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, Revised 2003 Consensus on diagnostic criteria and long-term health risk related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19(1), 41–47 (2004)CrossRef
26.
go back to reference D. Ferriman, J. Gallwey, Clinical assessment of body hair growth in woman. J. Clin. Endocrinol. Metab. 21, 1440–1447 (1961)CrossRefPubMed D. Ferriman, J. Gallwey, Clinical assessment of body hair growth in woman. J. Clin. Endocrinol. Metab. 21, 1440–1447 (1961)CrossRefPubMed
27.
go back to reference A.M. Fulghesu, S. Angioni, E. Frau, C. Belosi, R. Apa, R. Mioni, N. Xamin, G.P. Capobianco, S. Desolle, F. Fruzzetti, V. Lazzarini, L. Minerva, G.B. Melis, A. Lanzone, Ultrasound in polycystic ovary syndrome—the measuring of ovarian stroma and relationship with circulating androgens: results of a multicentric study. Hum. Reprod. 22(9), 2501–2508 (2007)CrossRefPubMed A.M. Fulghesu, S. Angioni, E. Frau, C. Belosi, R. Apa, R. Mioni, N. Xamin, G.P. Capobianco, S. Desolle, F. Fruzzetti, V. Lazzarini, L. Minerva, G.B. Melis, A. Lanzone, Ultrasound in polycystic ovary syndrome—the measuring of ovarian stroma and relationship with circulating androgens: results of a multicentric study. Hum. Reprod. 22(9), 2501–2508 (2007)CrossRefPubMed
28.
go back to reference B.E. Ainsworth, W.L. Haskell, M.C. Whitt, M.L. Irwin, A.M. Swartz, S.J. Strath, W.L. O’Brien, D.R. Bassett Jr, K.H. Schmitz, P.O. Emplaincourt, D.R. Jacobs Jr, A.S. Leon, Compendium of physicals activities: an update of physical codes and MET intensities. Med. Sci. Sports Exerc. 32(9 suppl), S498–S504 (2000)CrossRefPubMed B.E. Ainsworth, W.L. Haskell, M.C. Whitt, M.L. Irwin, A.M. Swartz, S.J. Strath, W.L. O’Brien, D.R. Bassett Jr, K.H. Schmitz, P.O. Emplaincourt, D.R. Jacobs Jr, A.S. Leon, Compendium of physicals activities: an update of physical codes and MET intensities. Med. Sci. Sports Exerc. 32(9 suppl), S498–S504 (2000)CrossRefPubMed
29.
go back to reference M. Matsuda, R.A. DeFronzo, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462–1470 (1999)CrossRefPubMed M. Matsuda, R.A. DeFronzo, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462–1470 (1999)CrossRefPubMed
30.
go back to reference American Diabetes Association, Screening for type 2 diabetes. Diabetes Care 27, 11–14 (2004)CrossRef American Diabetes Association, Screening for type 2 diabetes. Diabetes Care 27, 11–14 (2004)CrossRef
31.
go back to reference American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 29(Suppl 1), S43–S48 (2009) American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 29(Suppl 1), S43–S48 (2009)
32.
go back to reference B. Mozzanega, R. Mioni, M. Granzotto, S. Chiarelli, N. Xamin, L. Zuliani, N. Sicolo, D. Marchesoni, R. Vettor, Obesity reduces the expression of GLUT4 in the endometrium of normoinsulinemic women affected by the polycystic ovary syndrome. Ann. N.Y. Acad. Sci. 1034, 364–374 (2004)CrossRefPubMed B. Mozzanega, R. Mioni, M. Granzotto, S. Chiarelli, N. Xamin, L. Zuliani, N. Sicolo, D. Marchesoni, R. Vettor, Obesity reduces the expression of GLUT4 in the endometrium of normoinsulinemic women affected by the polycystic ovary syndrome. Ann. N.Y. Acad. Sci. 1034, 364–374 (2004)CrossRefPubMed
33.
go back to reference R. Mioni, B. Mozzanega, M. Granzotto, A. Pierobon, L. Zuliani, P. Maffei, S. Blandamura, S. Grassi, N. Sicolo, R. Vettor, Insulin receptor and glucose transporters mRNA expression throughout the menstrual cycle in human endometrium: a physiological and cyclical condition of tissue insulin resistance. Gynecol. Endocrinol. 28(12), 1014–1018 (2012)CrossRefPubMed R. Mioni, B. Mozzanega, M. Granzotto, A. Pierobon, L. Zuliani, P. Maffei, S. Blandamura, S. Grassi, N. Sicolo, R. Vettor, Insulin receptor and glucose transporters mRNA expression throughout the menstrual cycle in human endometrium: a physiological and cyclical condition of tissue insulin resistance. Gynecol. Endocrinol. 28(12), 1014–1018 (2012)CrossRefPubMed
34.
go back to reference E. Bonora, S. Kiechl, J. Willeit, F. Oberhollenzer, G. Egger, J.B. Meigs, R.C. Bonadonna, M. Muggeo, Insulin resistance as estimated by HOmeostasis Model Assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population. Diabetes Care 30(2), 318–324 (2007)CrossRefPubMed E. Bonora, S. Kiechl, J. Willeit, F. Oberhollenzer, G. Egger, J.B. Meigs, R.C. Bonadonna, M. Muggeo, Insulin resistance as estimated by HOmeostasis Model Assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population. Diabetes Care 30(2), 318–324 (2007)CrossRefPubMed
35.
go back to reference M. Gallea, M. Granzotto, S. Azzolini, D. Faggian, B. Mozzanega, R. Vettor, R. Mioni, Insulin and body weight but not hyperandrogenism seem involved in seasonal serum 25-OH-vitamin D3 levels in subjects affected by PCOS. Gynecol. Endocrinol. 30(10), 739–745 (2014)CrossRefPubMed M. Gallea, M. Granzotto, S. Azzolini, D. Faggian, B. Mozzanega, R. Vettor, R. Mioni, Insulin and body weight but not hyperandrogenism seem involved in seasonal serum 25-OH-vitamin D3 levels in subjects affected by PCOS. Gynecol. Endocrinol. 30(10), 739–745 (2014)CrossRefPubMed
36.
go back to reference A.J. Garber, M.J. Abrahamson, J.I. Barzilay, L. Blond, Z.T. Bloomgarden, S. Dagogo-Jack, M.B. Davidson, D. Einhorn, J.R. Garber, W.T. Garwey, G. Grumberger, Y. Haldelsman, I.B. Hirsh, P.S. Jellinger, J.B. McGill, J.I. Mechanick, P.D. Rosenblit, G.E. Umplerrez, Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—executive summary. Endocr. Pract. 21(12), 1403–1414 (2015)CrossRefPubMed A.J. Garber, M.J. Abrahamson, J.I. Barzilay, L. Blond, Z.T. Bloomgarden, S. Dagogo-Jack, M.B. Davidson, D. Einhorn, J.R. Garber, W.T. Garwey, G. Grumberger, Y. Haldelsman, I.B. Hirsh, P.S. Jellinger, J.B. McGill, J.I. Mechanick, P.D. Rosenblit, G.E. Umplerrez, Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—executive summary. Endocr. Pract. 21(12), 1403–1414 (2015)CrossRefPubMed
37.
go back to reference G. Mancia, R. Fagard, K. Narkiewicz, J. Redon, A. Zanchetti, M. Bohm, T. Christiaens, R. Cifkova, G. De Backer, A. Dominiczak, M. Galderisi, D.E. Grobbee, T. Jaarsma, P. Kirchhof, S.E. Kjeldsen, S. Laurent, A.J. Manolis, P.M. Nilsson, L.M. Ruilope, R.E. Schmieder, P.A. Sirnes, P. Sleight, M. Viigimaa, B. Waeber, F. Zannad, Task Force Members, 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 31, 1281–1357 (2013)CrossRefPubMed G. Mancia, R. Fagard, K. Narkiewicz, J. Redon, A. Zanchetti, M. Bohm, T. Christiaens, R. Cifkova, G. De Backer, A. Dominiczak, M. Galderisi, D.E. Grobbee, T. Jaarsma, P. Kirchhof, S.E. Kjeldsen, S. Laurent, A.J. Manolis, P.M. Nilsson, L.M. Ruilope, R.E. Schmieder, P.A. Sirnes, P. Sleight, M. Viigimaa, B. Waeber, F. Zannad, Task Force Members, 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 31, 1281–1357 (2013)CrossRefPubMed
38.
go back to reference R. Mioni, S. Chiarelli, N. Xamin, L. Zuliani, M. Granzotto, B. Mozzanega, P. Maffei, C. Martini, S. Blandamura, N. Sicolo, R. Vettor, Evidence for the presence of glucose transporter 4 in the endometrium and its regulation in polycystic ovary syndrome patients. J. Clin. Endocrinol. Metab. 89(8), 4089–4096 (2004)CrossRefPubMed R. Mioni, S. Chiarelli, N. Xamin, L. Zuliani, M. Granzotto, B. Mozzanega, P. Maffei, C. Martini, S. Blandamura, N. Sicolo, R. Vettor, Evidence for the presence of glucose transporter 4 in the endometrium and its regulation in polycystic ovary syndrome patients. J. Clin. Endocrinol. Metab. 89(8), 4089–4096 (2004)CrossRefPubMed
39.
go back to reference P. Della Mea, M. Lupia, V. Bandolin, S. Guzzon, N. Sonino, R. Vettor, F. Fallo, Adiponectin, insulin resistance and left ventricular structure in dipper and no dipper essential hypertensive patients. Am. J. Hypertens. 18(1), 30–35 (2005)CrossRefPubMed P. Della Mea, M. Lupia, V. Bandolin, S. Guzzon, N. Sonino, R. Vettor, F. Fallo, Adiponectin, insulin resistance and left ventricular structure in dipper and no dipper essential hypertensive patients. Am. J. Hypertens. 18(1), 30–35 (2005)CrossRefPubMed
40.
go back to reference F. Orio Jr, S. Palomba, L. Spinelli, T. Cascella, L. Tauchmanova, F. Zullo, G. Lombardi, A. Colao, The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J. Clin. Endocrinol. Metab. 89(8), 3696–3701 (2004)CrossRefPubMed F. Orio Jr, S. Palomba, L. Spinelli, T. Cascella, L. Tauchmanova, F. Zullo, G. Lombardi, A. Colao, The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J. Clin. Endocrinol. Metab. 89(8), 3696–3701 (2004)CrossRefPubMed
41.
go back to reference F. Vetta, P. Cicconetti, S. Ronzoni, V. Rizzo, L. Palleschi, G. Canarile, M.R. Lupattelli, M. Migliori, S. Morelli, V. Marigliano, Hyperinsulinaemia, regional adipose tissue distribution and left ventricular mass in normotensive, elderly, obese subjects. Eur. Heart J. 19(2), 326–331 (1998)CrossRefPubMed F. Vetta, P. Cicconetti, S. Ronzoni, V. Rizzo, L. Palleschi, G. Canarile, M.R. Lupattelli, M. Migliori, S. Morelli, V. Marigliano, Hyperinsulinaemia, regional adipose tissue distribution and left ventricular mass in normotensive, elderly, obese subjects. Eur. Heart J. 19(2), 326–331 (1998)CrossRefPubMed
42.
go back to reference I. Vaněčková, L. Maletínská, M. Behuliak, V. Nagelová, J. Zicha, J. Kuneš, Obesity-related hypertension: possible pathophysiological mechanisms. J. Endocrinol. 223(3), R63–R78 (2015)CrossRef I. Vaněčková, L. Maletínská, M. Behuliak, V. Nagelová, J. Zicha, J. Kuneš, Obesity-related hypertension: possible pathophysiological mechanisms. J. Endocrinol. 223(3), R63–R78 (2015)CrossRef
43.
go back to reference C. Manrique, J.R. Sowers, Insulin resistance and skeletal muscle vasculature: significance, assessment and therapeutic modulators. Cardiorenal Med. 4, 244–256 (2014)CrossRefPubMedPubMedCentral C. Manrique, J.R. Sowers, Insulin resistance and skeletal muscle vasculature: significance, assessment and therapeutic modulators. Cardiorenal Med. 4, 244–256 (2014)CrossRefPubMedPubMedCentral
44.
go back to reference Y. Imai, K. Abe, M. Munakata, H. Sakuma, J. Hashimoto, K. Imai, H. Sekino, K. Yoshinaga, Circadian blood pressure variations under different pathophysiological conditions. J. Hypertens. 8(Suppl 7), S125–S132 (1990) Y. Imai, K. Abe, M. Munakata, H. Sakuma, J. Hashimoto, K. Imai, H. Sekino, K. Yoshinaga, Circadian blood pressure variations under different pathophysiological conditions. J. Hypertens. 8(Suppl 7), S125–S132 (1990)
45.
go back to reference M. Emdin, A. Gastaldelli, E. Muscelli, A. Macerata, A. Natali, S. Camastra, E. Ferranini, Hyperinsulinemia and Autonomic Nervous System Dysfunction in Obesity Effects of Weight Loss. Circulation 103(4), 513–519 (2001)CrossRefPubMed M. Emdin, A. Gastaldelli, E. Muscelli, A. Macerata, A. Natali, S. Camastra, E. Ferranini, Hyperinsulinemia and Autonomic Nervous System Dysfunction in Obesity Effects of Weight Loss. Circulation 103(4), 513–519 (2001)CrossRefPubMed
46.
go back to reference G. Pal, C. Adithan, P.H. Ananthanarayanan, P. Pal, N. Nanda, D. Thiyagarajan, A.N. Syamsunderkiran, V. Lalitha, T.K. Dutta, Association of sympathovagal imbalance with cardiovascular risks in young prehypertensives. Am. J. Cardiol. 112(11), 1757–1762 (2013)CrossRefPubMed G. Pal, C. Adithan, P.H. Ananthanarayanan, P. Pal, N. Nanda, D. Thiyagarajan, A.N. Syamsunderkiran, V. Lalitha, T.K. Dutta, Association of sympathovagal imbalance with cardiovascular risks in young prehypertensives. Am. J. Cardiol. 112(11), 1757–1762 (2013)CrossRefPubMed
47.
go back to reference P. Palatini, Role of elevated heart rate in the development of cardiovascular disease in hypertension. Hypertension 58(5), 745–750 (2011)CrossRefPubMed P. Palatini, Role of elevated heart rate in the development of cardiovascular disease in hypertension. Hypertension 58(5), 745–750 (2011)CrossRefPubMed
48.
go back to reference P. Palatini, G. Parati, Persistently elevated heart rate accelerates the progression of arterial stiffness. J. Hypertens. 28, 653–656 (2010)CrossRefPubMed P. Palatini, G. Parati, Persistently elevated heart rate accelerates the progression of arterial stiffness. J. Hypertens. 28, 653–656 (2010)CrossRefPubMed
49.
go back to reference D. Garcia-Labbé, E. Ruka, O.F. Bertrand, P. Voisine, O. Costerousse, P. Poirier, Obesity and coronary artery disease: evaluation and treatment. Can. J. Cardiol. 31(2), 184–194 (2015)CrossRefPubMed D. Garcia-Labbé, E. Ruka, O.F. Bertrand, P. Voisine, O. Costerousse, P. Poirier, Obesity and coronary artery disease: evaluation and treatment. Can. J. Cardiol. 31(2), 184–194 (2015)CrossRefPubMed
50.
go back to reference J.P. Després, Obesity and cardiovascular disease: weight loss is not the only target. Can. J. Cardiol. 31(2), 216–222 (2015)CrossRefPubMed J.P. Després, Obesity and cardiovascular disease: weight loss is not the only target. Can. J. Cardiol. 31(2), 216–222 (2015)CrossRefPubMed
51.
go back to reference M. Luque-Ramírez, F. Álvarez-Blasco, C. Mendieta-Azcona, J.I. Botella-Carretero, H.F. Escobar-Morreale, Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92(6), 2141–2148 (2007)CrossRefPubMed M. Luque-Ramírez, F. Álvarez-Blasco, C. Mendieta-Azcona, J.I. Botella-Carretero, H.F. Escobar-Morreale, Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92(6), 2141–2148 (2007)CrossRefPubMed
52.
go back to reference M. Luque-Ramírez, D. Martí, E. Fernández-Durán, M. Alpañés, F. Álvarez-Blasco, H.F. Escobar-Morreale, Office blood pressure, ambulatory blood pressure monitoring, and echocardiographic abnormalities in women with polycystic ovary syndrome: role of obesity and androgen excess. Hypertension 63(3), 624–629 (2014)CrossRefPubMed M. Luque-Ramírez, D. Martí, E. Fernández-Durán, M. Alpañés, F. Álvarez-Blasco, H.F. Escobar-Morreale, Office blood pressure, ambulatory blood pressure monitoring, and echocardiographic abnormalities in women with polycystic ovary syndrome: role of obesity and androgen excess. Hypertension 63(3), 624–629 (2014)CrossRefPubMed
Metadata
Title
Hyperinsulinemia and obese phenotype differently influence blood pressure in young normotensive patients with polycystic ovary syndrome
Authors
Roberto Mioni
Anna Dalla Cà
Jenni Turra
Sara Azzolini
Nadia Xamin
Luigi Bleve
Pietro Maffei
Roberto Vettor
Francesco Fallo
Publication date
01-02-2017
Publisher
Springer US
Published in
Endocrine / Issue 2/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-0958-x

Other articles of this Issue 2/2017

Endocrine 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.